Insider Transactions in Q1 2024 at An2 Therapeutics, Inc. (ANTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,000
+49.47%
|
-
|
|
Mar 15
2024
|
Paul Eckburg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+36.85%
|
-
|
|
Mar 15
2024
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+49.34%
|
-
|
|
Mar 15
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.45%
|
-
|
|
Mar 15
2024
|
Joshua M Eizen Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.04%
|
-
|
|
Mar 15
2024
|
Lucy Day Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+47.31%
|
-
|
|
Jan 18
2024
|
Joseph S Zakrzewski |
SELL
Open market or private sale
|
Indirect |
100,000
-19.77%
|
$1,900,000
$19.11 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
15,907
-4.04%
|
$302,233
$19.65 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
84,093
-4.04%
|
$1,597,767
$19.65 P/Share
|
|
Jan 16
2024
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
100,000
-4.04%
|
$1,900,000
$19.65 P/Share
|
|
Jan 12
2024
|
Robin Shane Readnour |
SELL
Open market or private sale
|
Indirect |
1,425
-0.16%
|
$29,925
$21.92 P/Share
|
|
Jan 10
2024
|
Robin Shane Readnour |
SELL
Open market or private sale
|
Indirect |
3,669
-0.41%
|
$77,049
$21.93 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,417
-79.49%
|
$148,340
$20.14 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,417
+35.35%
|
$22,251
$3.51 P/Share
|
|
Jan 02
2024
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,777
-56.59%
|
$55,540
$20.09 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,583
-57.44%
|
$51,660
$20.12 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,583
+36.48%
|
$0
$0.42 P/Share
|